Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.48 |
| ▸ | SKP1 | P63208 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542791 | 1.00 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT | |
| SCHEMBL30542725 | 1.00 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT | |
| SCHEMBL15252451 | 0.95 | MAPT (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT | |
| SCHEMBL17054767 | 0.94 | MAP4K4 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT | |
| SCHEMBL17055303 | 0.94 | MAP4K4 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT | |
| SCHEMBL25374207 | 0.94 | MAP4K4 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT | |
| SCHEMBL29744447 | 0.94 | MAP4K4 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT | |
| SCHEMBL31256861 | 0.94 | MAP4K4 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT | |
| SCHEMBL3702193 | 0.85 | MAPT (0.56) | MAPTCKS1BSKP1SKP2PIM1 | |
| SCHEMBL13418950 | 0.84 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| EP-4482839-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
| WO-2023158862-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20170183352-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170183352-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-9670202-B2 | Substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-06 | — | — | US | disclosed |
| EP-3004092-B1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-8415355-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415355-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415355-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | CHRNB2 4855/4885CHRNB4 4865/4885CHRNA3 4793/4885 |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CHRNB2 4852/4885CHRNB4 4799/4885CHRNA3 4806/4885 |
| US-20170183352-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CHRNB2 4852/4885CHRNB4 4799/4885CHRNA3 4806/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CHRNB2 4852/4885CHRNB4 4799/4885CHRNA3 4806/4885 |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CHRNB2 4852/4885CHRNB4 4799/4885CHRNA3 4806/4885 |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CHRNB2 4852/4885CHRNB4 4799/4885CHRNA3 4806/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CHRNB2 4852/4885CHRNB4 4799/4885CHRNA3 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.